Florida Medical Marijuana Dispensations Hit 16.36B Milligrams THC in 2026
Florida's medical cannabis program dispensed over 16 billion milligrams of THC and 5.6 million ounces of flower through September 2026.

Close-up of hands holding cannabis buds, showcasing detail and texture.
Record Dispensations Signal Market Maturity
Florida's medical marijuana program has dispensed 16.36 billion milligrams of THC and 5.62 million ounces of flower through the first nine months of 2026. The figures represent a continuation of steady growth in the state's medical cannabis market, now serving over 800,000 active patients across 22 licensed medical marijuana treatment centers.
The cleanest read on these numbers? Market maturity, not explosive expansion. Florida's MMJ program has been operational since 2017, and 2026 dispensation rates track closely with late-2025 monthly averages. The state's vertical-integration model limits license holders but ensures supply stability.
Florida's Office of Medical Marijuana Use reports dispensation data monthly. The 16.36 billion milligrams of THC figure includes all product forms: flower, concentrates, edibles, and topicals. Smokable cannabis alone accounts for 5.62 million ounces, making flower the most popular product category among Florida patients.
What the Numbers Mean for Operators
At current dispensation rates, Florida's medical program is on pace to exceed 21 billion milligrams of THC dispensed by year-end 2026. That volume supports an estimated $2.1 billion in annual medical sales, according to industry analysts tracking the state's vertically integrated market.
Twenty-two licensed operators include Trulieve, Curaleaf, Verano, and AYR Wellness. Trulieve holds approximately 50% market share statewide. The vertical-integration requirement means each license holder cultivates, processes, and dispenses its own products through company-owned retail locations.
Florida doesn't cap dispensary counts per license holder. Trulieve operates over 120 locations statewide. Patient count has grown 6% year-over-year—slower than the double-digit growth rates seen in 2020-2023, but steady enough to support continued retail expansion by the largest MSOs.
Adult-Use Vote Looms Over Medical Market
Florida voters will decide on Amendment 3, a constitutional amendment legalizing adult-use cannabis, in November 2026. If passed, the amendment would allow adults 21 and over to purchase and possess up to three ounces of cannabis. Existing medical marijuana treatment centers would be authorized to serve adult-use customers immediately.
The vote creates a binary outcome for operators. Passage would unlock a market estimated at $6 billion in annual adult-use sales by 2028, according to projections from cannabis analytics firms. Failure? The medical-only framework stays intact, with growth limited to patient-count increases and per-patient consumption trends.
Trulieve has committed over $60 million to the Smart & Safe Florida campaign backing Amendment 3, and the company's market dominance positions it to capture the largest share of adult-use revenue if the measure passes. For full background on this story, see the CannIntel topic hub on Florida's medical marijuana program.
We'll be watching October dispensation data and November ballot results. The next inflection point is the vote.
Sources
The cannabis newsletter you forward to your team.
Federal policy, market data, grower alerts, and the one story that matters today. Sent every weekday at 7am. Free.
No spam. Unsubscribe with one click. 21+ only.
Related from Business

Nebraska MMJ Growers Harvest First Crops With No Buyers Yet
Nebraska's first medical cannabis harvests are coming in before any processor, transporter, lab or dispensary exists to take delivery, MJBizDaily reported.

Organigram enters fight for Aurora as Curaleaf bid clock runs
British American Tobacco's stake in Organigram could put the tobacco giant at the center of the Aurora contest before Curaleaf's offer expires Dec. 4.

Tilray Medical Wins Approval for In-House EU-GMP Cannabis Testing
Tilray Medical can now run EU-GMP quality testing in-house, a move that could shift lab costs and batch-release timing, though key details remain undisclosed.
More from the newsroom

Cannabis Reform Foes Cite GAO in Push to Reopen Hearings
Opponents of cannabis reform pointed to a GAO document to argue for reopening hearings, Law360 reported, though the filing's forum and contents remain unconfirmed.

South Dakota AG Says Medical Marijuana Law Meets Rescheduling
A South Dakota attorney general's legal opinion concludes the state's existing medical marijuana laws need no changes to comply with federal rescheduling, a position other states may adopt.

DEA Judge Orders New Replies as Marijuana Rescheduling Stays Stalled
A DEA administrative law judge ordered fresh replies in the Schedule III proceeding, which remains sidelined with no final rule in sight.